Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Contrast Sensitivity Function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Contrast Sensitivity Function. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2022-000174-25 Sponsor Protocol Number: 101090401IN Start Date*: 2023-03-17
    Sponsor Name:SANTEN INCORPORATED
    Full Title: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehi...
    Medical condition: Fuchs Endothelial Corneal Dystrophy (FECD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10014823 Endothelial corneal dystrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022791-31 Sponsor Protocol Number: D01092010AZNTG Start Date*: Information not available in EudraCT
    Sponsor Name:University Erlangen-Nuremberg
    Full Title: Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®
    Medical condition: The effect of AZARGA(R) on the central and spacial-temporal contrast sensitivity of patients with normal tension glaucoma will be examined. Healthy controls are required to prove the disease specif...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019279 Heart failure LLT
    12.1 10003555 Asthma bronchial LLT
    12.1 10021005 Hypoglycemia LLT
    12.1 10000456 Acid base balance LLT
    12.1 10054844 Anaphylactic reaction to drug LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-004142-35 Sponsor Protocol Number: ABSALON Start Date*: 2023-04-18
    Sponsor Name:Department of Ophthalmology, Rigshospitalet
    Full Title: Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON)
    Medical condition: mild and moderate glaucoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10036719 Primary open angle glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002588-17 Sponsor Protocol Number: SAM-IIT01 Start Date*: 2019-10-21
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents
    Medical condition: Myopia
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002873-80 Sponsor Protocol Number: AMILCA-DIFLU Start Date*: 2020-01-14
    Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE
    Full Title: Unicentre, open, uncontrolled clinical trial to assess the morphological, biochemical and functional effects of Diflunisal treatment in patients with transthyretin cardiac amyloidosis
    Medical condition: transthyretin cardiac amyloidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004203-39 Sponsor Protocol Number: FNKV-OFT-2013-1 Start Date*: 2014-04-03
    Sponsor Name:Fakultní nemocnice Královské Vinohrady
    Full Title: A randomized, 12 months, active controlled study of the efficacy of repeated doses of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy
    Medical condition: prolipherative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001874-32 Sponsor Protocol Number: RDC-CNGA3-01 Start Date*: 2015-09-09
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observe...
    Medical condition: CNGA3-linked achromatopsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000454 Achromatopsia LLT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004700-20 Sponsor Protocol Number: 2104-02 Start Date*: 2005-03-11
    Sponsor Name:Epix Pharmaceuticals, Inc.
    Full Title: Phase II Feasibility study of safety and efficacy of Magnetic Resonance Imaging of Thrombi with EP-2104R in the detection in Venous Thromboembolism (VTE)
    Medical condition: Detection of venous thromboembolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000900-15 Sponsor Protocol Number: B7A-MC-MBCU Start Date*: 2005-08-19
    Sponsor Name:Eli Lilly and Company
    Full Title: The effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography
    Medical condition: Diabetic Macular Edema (DME), is the most common cause of visual impairment in patients with diabetic retinopathy (DR). It is the accumulation of extracellular fluid in the retinal tissues of the m...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) DE (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004701-23 Sponsor Protocol Number: 2104-03 Start Date*: 2005-03-14
    Sponsor Name:Epix Pharmaceuticals, Inc.
    Full Title: Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers
    Medical condition: Detection of thrombi in the arterial vasculature and cardiac chambers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000730-19 Sponsor Protocol Number: DC2019ROCKIES1 Start Date*: 2020-03-05
    Sponsor Name:Amsterdam Univeristy Medical Center - Vu Univeristy Medical Center
    Full Title: A phase 4, monocenter, prospective, randomized, placebo-controlled, double-blind, cross-over mechanistic intervention trial to assess effect of 4-week Ertugliflozin (SGLT-2 inhibitor) therapy on re...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021722-35 Sponsor Protocol Number: HYKP1015 Start Date*: 2010-10-08
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Diabetic macula oedema: A prospective randomised study comparing the detailed functional and anatomical changes of repeated pan anti-VEGF therapy with ranibizumab versus conventional macular laser ...
    Medical condition: Diabetic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    10057915 Diabetic Macular Oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002373-95 Sponsor Protocol Number: 270682 Start Date*: 2021-01-07
    Sponsor Name:Haukeland University Hospital
    Full Title: Study of Mesenchymal Autologous stem cells as Regenerative Treatment for Multiple Sclerosis
    Medical condition: Multiple sclerosis (MS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003253-36 Sponsor Protocol Number: LBS-008-CT03 Start Date*: Information not available in EudraCT
    Sponsor Name:Belite Bio, Inc
    Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
    Medical condition: Stargardt Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003631-21 Sponsor Protocol Number: CLNA043A12203 Start Date*: 2021-06-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, four-arm, canakinumab placebo-controlled, participant, investigator and sponsor-blinded study investigating the safety, tolerability and efficacy of intra-articular canakinumab follow...
    Medical condition: osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Ongoing) EE (Ongoing) LT (Completed) LV (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2005-003517-33 Sponsor Protocol Number: CRFB002A2302 Start Date*: 2005-11-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal...
    Medical condition: Male and female patients ≥50 years of age with either with predominantly classic, minimally classic, or occult lesions with no classic component, all with primary or recurrent subfoveal CNV seconda...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) DE (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) IT (Completed) BE (Completed) FI (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002696-10 Sponsor Protocol Number: CCPK850X2202 Start Date*: 2018-05-09
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa c...
    Medical condition: retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004981-16 Sponsor Protocol Number: 1991-201-008 Start Date*: 2022-06-17
    Sponsor Name:Editas Medicine, Inc.
    Full Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Cen...
    Medical condition: Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in I...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10015920 Eye disorders congenital HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003705-34 Sponsor Protocol Number: RDC-PDE6A-01 Start Date*: 2019-07-02
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: PIGMENT – PDE6A gene therapy for retinitis pigmentosa
    Medical condition: PDE6A-linked retinitis pigmentosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10010464 Congenital eye disorders NEC HLT
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007232-18 Sponsor Protocol Number: CRFB002AHU04T Start Date*: 2009-03-19
    Sponsor Name:University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology [...]
    1. University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology
    2. Semmelweis University Department of Ophthalmology
    3. Cholnoky F. County Hospital Veszprém Department of Ophthalmology
    Full Title: Comparison of the effect of intravitreal ranibizumab injections compared to macular grid-pattern laser therapy for the symptomatic treatment of diabetic macular edema (a randomized, controlled, pha...
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA